Eloralintide

1. 01Bloodstream

   Given under the skin, then a slow, steady level in the blood

   In trials the medicine is injected under the skin once a week. A fatty side chain lets it cling to a blood protein called albumin, so it leaves the body very slowly. Its level stays fairly even all week.

   For experts

   Lys26 is acylated (gamma-Glu-gamma-Glu-C20 diacid) to bind albumin. In people with obesity, absorption after subcutaneous dosing is slow, the half-life is about 14 days, exposure is dose-proportional, and steady-state peak-to-trough ratios are 1.28 to 1.38. The authors suggest this flat profile may help gastrointestinal tolerability (an indirect inference, not a tested result).[src][src]

2. 02Brain

   It switches on amylin receptors, mostly the AMY1 type

   Amylin receptors are found in the brain. In mice, a related drug needed these receptors to lower body weight, and it switched on nerve cells in the brainstem. In lab tests on cells, eloralintide switched on the AMY1 type much more strongly than a nearby receptor for a different hormone, calcitonin.

   For experts

   Amylin receptors are heterodimers of the calcitonin receptor with RAMP1 (AMY1R) or RAMP3 (AMY3R). In cell-line cAMP assays eloralintide was about 12-fold more potent at human AMY1R (EC50 23.9 pM) than at the human calcitonin receptor and about 11-fold more potent than at human AMY3R; in rat receptors both AMY1R and AMY3R were activated more potently than the calcitonin receptor. This is receptor pharmacology in cells. Where in the human brain it acts has not been shown for eloralintide; a mouse study of the related agonist cagrilintide found its weight-lowering effect depended on RAMP1/RAMP3 and activated hindbrain neurons (animal-only evidence for a different molecule).[src][src]

3. 03Brain

   The brain gets a stronger 'I am full' message

   Natural amylin helps end a meal. Eloralintide is thought to do the same job for longer, so people eat less. In trials, some people reported a smaller appetite.

   For experts

   Native amylin promotes meal termination through central mechanisms. Lilly states the effects of eloralintide are likely mediated by affecting satiety. In the multiple-ascending-dose study, decreased appetite was the most common adverse event (19% of eloralintide-treated participants), and fasting appetite scores showed only a non-significant trend toward lower appetite. The mechanism is inferred from receptor pharmacology, animal data and the class; none of the sources cited here measured satiety pathways directly in people.[src][src][src]

4. 04Stomach

   Natural amylin slows the stomach and calms glucagon; for eloralintide the effect looks small

   Natural amylin does two other things after a meal. It slows how fast the stomach empties, and it turns down glucagon, a hormone that raises blood sugar. In a small 12-week study, eloralintide slowed the stomach only a little after the first dose, and this faded with weekly use. Fasting glucagon went down a little, but the change could have been chance.

   For experts

   Class physiology: amylin is co-secreted with insulin from pancreatic beta cells, slows gastric emptying and suppresses glucagon secretion (review). For eloralintide itself, the 12-week phase 1 multiple-ascending-dose study used acetaminophen absorption as a gastric-emptying marker: higher doses modestly lowered acetaminophen exposure after the first dose, exposure returned toward baseline by Day 80, and acetaminophen tmax did not differ significantly from placebo. The authors say any gastric-emptying effect may be transient and that this needs confirmation. Fasting glucagon decreased non-significantly without a consistent dose relationship, and fasting glucose was essentially unchanged in this normoglycaemic population. In the phase 2 trial Lilly reported improved glycemic control measures in participants without type 2 diabetes.[src][src][src]

5. 05Fat tissue

   In rats, most of the lost weight was fat

   In rats fed a fattening diet, eloralintide lowered food intake and body weight, and most of the weight lost was fat rather than lean mass (muscle, bone and water). This is animal evidence only. It has not been measured the same way in people in the sources we checked.

   For experts

   Animal-only evidence: in diet-induced obese rats given repeated doses, eloralintide dose-dependently reduced food intake and body weight, and fat mass accounted for about 85%, 77% and 68% of the weight lost across three increasing dose levels. In lean rats, eloralintide produced less conditioned taste avoidance than cagrilintide at a similar 24-hour food-intake reduction (p < 0.05), a proxy for aversion. Body-composition results in humans from the phase 2 trial are not reported in the cited abstract.[src]

6. 06Fat tissue

   In people, weight and waist size fell over 48 weeks

   In the 48-week trial, every eloralintide group lost more weight than the placebo group. The average loss went from about 9% to about 20% of body weight, depending on the group. Waist size also went down.

   For experts

   Phase 2 (n = 263, adults with obesity or overweight without type 2 diabetes): mean percent change in body weight at 48 weeks (efficacy estimand) ranged from -9.5% to -20.1% across arms versus -0.4% on placebo (Lilly press release; Lancet abstract reports rounded values with confidence intervals). Waist circumference also improved. These are company-funded results, not adjusted for multiplicity in Lilly's summary.[src][src]

7. 07Heart

   Some heart and metabolic health markers moved the right way

   Along with weight, the company reported better blood pressure, blood fats and signs of inflammation. These are markers, not proof of fewer heart attacks. Longer studies would be needed to show that.

   For experts

   Lilly reports that eloralintide was associated with improvements in waist circumference, blood pressure, lipid profiles, glycemic control and markers of inflammation in the phase 2 trial; the release gives no figures for these outcomes. No cardiovascular outcomes trial of eloralintide has reported; effects on hard cardiovascular events are unknown.[src]

Around the world

Is Eloralintide legal where you live?

Related molecules